AMENDMENTS

Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

1-13. (Canceled)

- 14. (Currently amended) A method for decreasing cellular replication in a GnRH-receptor positive tumor in a subject selected from the group consisting of a malignant tumor originating in one or more of the brain, the nervous system, or meninges of the brain; Ewing sarcoma; Kaposis sarcoma; and malignant melanoma, said method comprising administering to said subject a replication decreasing amount of one or more of a GnRH agonist or GnRH antagonist, said GnRH agonist or antagonist being a GnRH analogue selected from the group leuprorelin, triptorelin, buserelin, goserelin, Synarela[®], Cetrorelix[®], Antarelix[®], Antide[®], Ramorelix[®] or pharmacologically acceptable salts thereof, so as to decrease cellular replication in the GnRH-receptor positive tumor.
- (Previously presented) The method of claim 14 wherein the GnRH-receptor positive tumor is Kaposi sarcoma
- 16. (Previously presented) The method of claim 14 wherein the GnRH-receptor positive tumor is Glioblastoma multiforme, medulloblastoma, pinealoma, neuroblastoma, craniopharyngeoma, meningeoma, chordoma, Ewing sarcoma, malignant melanoma, or Kaposi sarcoma.
- (Currently amended) The method according to claim 14, wherein the GnRH agenistsagonist or GnRH antagonists areantagonist analogue used in combination with a cytotoxic substance.
- (Previously presented) The method of claim 14 wherein the GnRH-receptor positive tumor is malignant melanoma.

80003951.1 - 2 -

- 19. (Currently amended) A method for decreasing cellular replication in a GnRH-receptor positive tumor in a subject selected from the group consisting of a malignant tumor originating in one or more of the brain, the nervous system, or meninges of the brain; Ewing sarcoma; Kaposis sarcoma; and malignant melanoma, said method comprising administering to said subject a replication decreasing amount of a GnRH agonist or GnRH antagonist coupled to a cytotoxic substance, said GnRH agonist or GnRH antagonist being a GnRH analogue_selected from the group leuprorelin, triptorelin, buserelin, goserelin, nafarelin, Cetrorelix®, Antarelix®, Antide®, Ramorelix® or pharmacologically acceptable salts thereof, so as to decrease cellular replication in the GnRH-receptor positive tumor.
- 20. (Previously presented) The method of claim 19 wherein the GnRH-receptor positive tumor is malignant melanoma.

80003951.1 - 3 -